approved glp-1 agonists Comparing Ozempic, Wegovy and Other Drugs Comparing GLP-type therapies for weight

10.1016/j.metabol.2009.10.007 46 DhillonS

The lifestyle interventions should be monitored, adapted, and perpetuated in an informed consent with the patient over the years, regardless of whether additional medical or surgical therapy is started in the course of T2D or obesity (16, 17, 2325)

It was edited by Rebecca Ramirez

T lymphocytes in individuals suffering from chronic obstructive pulmonary disease (COPD) have been found to be immunodeficient, with an increased functional exhaustion of T cells that express PD-1, a negative co-stimulatory molecule linked to impaired immune responses [166]

However, a crucial limitation of the above studies is that the endpoint was pathologic (described as asymptomatic chronic pancreatitis), referring to histologic changes, rather than clinical 26

People with obesity are more likely to develop RA and then have worse RA symptoms